medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2012, Number 1

<< Back Next >>

Rev Invest Clin 2012; 64 (1)

Serum calcium is an independent prognostic factor of overall survival in Mexican patients with multiple myeloma

Maillet D, Montiel-Cervantes L, Padilla-González Y, Sánchez-Cortés E, Xolotl-Castillo M, Vela-Ojeda J, Reyes-Maldonado E

Language: English
References: 25
Page: 17-24
PDF size: 232.17 Kb.


ABSTRACT

Objective. To evaluate the impact of different prognostic factors that has been suggested to be useful in predicting the survival of patients with multiple myeloma (MM). Materials and methods. A longitudinal prospective study was conducted on 24 adult Mexican patients diagnosed with primary MM. The levels of expression of CD38, CD138 and cyclin D1 were analyzed in plasma cells (PCs) from patients and mononuclear cells from healthy donors. Serum levels of lactate dehydrogenase, creatinine, calcium, β2 microglobulin and interleukin-6 (IL-6) as well as hemoglobin and platelet count were taken into consideration. Results. CD138 and cyclin D1 levels in absolute numbers were significantly overexpressed in malignant PCs. A positive correlation was noted between cyclin D1 and CD38 expression levels in malignant PCs. IL-6 and serum calcium were also positively correlated in MM patients. Cyclin D1 overexpression was not associated with better overall survival (OS). Normal calcium levels were associated with better overall survival (OS). Serum calcium was the only variable correlating with better OS in Cox regression analysis. Conclusion. Serum calcium is an independent prognostic factor of OS in a population of Mexican patients with MM.


REFERENCES

  1. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842-54.

  2. Bataille R, Durie BGM, Grenier J. Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol 1983; 55: 439-47.

  3. Durie BGM, Stock-Novack D, Salmon SE, Finley P, Beckord J, Crowley J, Coltman CA. Prognostic value of pretreatment serum β2- microglobulin in myeloma: A Southwest Oncology Group study. Blood 1990; 75: 823-30.

  4. Ludwig H, Nachbaur DM, Fritz E, Krainer M, Huber H. Interleukin 6 is a prognostic factor in multiple myeloma. Blood 1991; 77: 2794-5.

  5. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and β2- microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80: 733-7.

  6. San Miguel JF, García-Sanz R, González M, Moro MJ, Hernández JM, Ortega F, et al. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 1995; 85: 448-55.

  7. Dewald GW, Kyle RA, Hicks GA, Greipp PR. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 1985; 66: 380-90.

  8. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletion of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86: 4250-6.

  9. Avet-Loiseau H, Facon T, Grosbois B, Magrangeas F, Rapp MJ, Harousseau JL, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002; 99: 2185-91.

  10. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004; 104: 607-18.

  11. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569-75.

  12. Smadja NV, Fruchart C, Isnard F, Louvet C, Dutel JL, Cheron N, et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia 1998; 12: 960-9.

  13. Avet-Loisseau, Li JY, Facon T, Brigaudeau C, Marineau N, Maloisel F, et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 1998; 58: 5640-5.

  14. Soverini S, Cavo M, Cellini C, Terragna C, Zamagni E, Ruggeri D, et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood 2003; 102: 1588-94.

  15. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21-33.

  16. Paiva B, Almeida J, Pérez-Andrés M, Mateo G, López A, Rasillo A, et al. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry Part B 2010; 78B: 239-52.

  17. Bataille R, Jégo G, Robillard N, Barillé-Nion S, Harousseau JL, Moreau P, et al. The phenotype of normal, reactive and malignant plasma cells. Identification of “many and multiple myelomas” and of new targets for myeloma therapy. Haematologica 2006; 91: 1234-40.

  18. Kawano MM, Mahmoud MS, Ishikawa H. Cyclin D1 and p16INK4A are preferentially expressed in immature and mature myeloma cells, respectively. Br J Haematol 1997; 99: 131-8.

  19. Uckum FM. Regulation of human B-cell ontogeny. Blood 1990; 76: 1908-23.

  20. Martínez-Hernández R, Cuervo-Sierra J, Solano-Genesta M, Gómez-Guijosa M, Cantú-Rodríguez O, Gutiérrez-Aguirre H, Gómez-Almaguer D. Mieloma múltiple en el Hospital Universitario de Monterrey: Experiencia clínica en un periodo de 7 años. Rev Hematol 2010; 11: 125-70 [Resúmenes del Congreso].

  21. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of Interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989; 84: 2008-11.

  22. De la Mata J, Uy HL, Guise TA, Story B, Boyce BF, Mundy GR, Roodman D. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest 1995; 95: 2846-52.

  23. Oyajobi BO. Multiple myeloma/hypercalcemia. Arthritis Res Ther 2007; 9(Suppl. 1): S4 [Doi:10.1186/ar2168].

  24. Abe M, Hiura K, Wilde J, Shioyasono A, Moriyana K, Hashimoto T. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004; 104: 2484-91.

  25. Rasmussen T, Knudsen LM, Johnsen HE. Frequency and prognostic relevance of cyclin D1 dysregulation in multiple myeloma. Eur J Haematol 2001; 67: 296-301.




2020     |     www.medigraphic.com